The mTOR/HIF-1a/HK2 axis determines metastatic potential of pancreatic cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043188

Enrollment

Unknown

Registered

2021-02-08

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with pancreatic ductal adenocarcinoma confirmed by operation and pathology; 2. Patients over 18 years old; 3. Patients who did not receive chemoradiotherapy or other anti-tumor therapy before operation; 4. Patients who agreed to participate in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other types of pancreatic cancer; 2. Patients with other tumors; 3. Patients with incomplete clinical information; 4. Patients with different opinions.

Design outcomes

Primary

Measure	Time frame
computed tomography;	—

Countries

China

Contacts

Public ContactShanshan Shen

Gulou Hospital Affiliated to Medical College of Nanjing University

datouwawa33@163.com+86 13584049527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026